Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells

HIV broadly neutralizing antibodies (bnAbs) can suppress viremia and protect against HIV infection. However, their elicitation is made difficult by low frequencies of appropriate precursor B cell receptors and the complex maturation pathways required to generate bnAbs from these precursors. Antibody genes can be engineered into B cells for expression as both a functional antigen receptor on cell surfaces and as secreted antibody. Here, we show that HIV bnAb-engineered primary mouse B cells can be adoptively transferred and vaccinated in immunocompetent mice resulting in the expansion of durable bnAb memory and long-lived plasma cells. Somatic hypermutation after immunization indicates that engineered cells have the capacity to respond to an evolving pathogen. These results encourage further exploration of engineered B cell vaccines as a strategy for durable elicitation of HIV bnAbs to protect against infection and as a contributor to a functional HIV cure.

Ingår i:Nature communications: Springer Science and Business Media LLC11:1, s. 5850-2041-1723

Av författaren/redakt...: Huang, DL; Tran, JT; Olson, A; Vollbrecht, T; Tenuta, M; Guryleva, MV; visa fler...; Fuller, RP; Schiffner, T; Abadejos, JR; Couvrette, L; Blane, TR; Saye, K; Li, WJ; Landais, E; Gonzalez-Martin, ...; Schief, W; Murrell, B; Burton, DR; Nemazee, D; Voss, JE; visa färre...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.